Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)
Name:
PIIS0923753424001054.pdf
Size:
628.9Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Parker, C. C.Petersen, P. M.
Cook, A. D.
Clarke, Noel W
Catton, C.
Cross, W. R.
Kynaston, H.
Parulekar, W. R.
Persad, R. A.
Saad, F.
Bower, L.
Durkan, G. C.
Logue, John
Maniatis, C.
Noor, D.
Payne, H.
Anderson, J.
Bahl, A. K.
Bashir, F.
Bottomley, D. M.
Brasso, K.
Capaldi, L.
Chung, C.
Cooke, P. W.
Donohue, J. F.
Eddy, B.
Heath, C. M.
Henderson, A.
Henry, A.
Jaganathan, R.
Jakobsen, H.
James, N. D.
Joseph, J.
Lees, K.
Lester, J.
Lindberg, H.
Makar, A.
Morris, S. L.
Oommen, N.
Ostler, P.
Owen, L.
Patel, P.
Pope, A.
Popert, R.
Raman, R.
Ramani, V.
Røder, A.
Sayers, I.
Simms, M.
Srinivasan, V.
Sundaram, S.
Tarver, K. L.
Tran, A.
Wells, P.
Wilson, J.
Zarkar, A. M.
Parmar, M. K. B.
Sydes, M. R.
Affiliation
Department of Urology, The Christie NHS Foundation Trust, Manchester; Manchester Cancer Research Centre, The University of Manchester, ManchesterIssue Date
2024
Metadata
Show full item recordAbstract
BACKGROUND: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for prostate-specific antigen (PSA) failure. PATIENTS AND METHODS: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, preoperative PSA≥10 ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT ('Adjuvant-RT') or an observation policy with salvage RT for PSA failure ('Salvage-RT') defined as PSA≥0.1 ng/ml or three consecutive rises. Stratification factors were Gleason score, margin status, planned RT schedule (52.5 Gy/20 fractions or 66 Gy/33 fractions) and treatment centre. The primary outcome measure was freedom-from-distant-metastasis (FFDM), designed with 80% power to detect an improvement from 90% with Salvage-RT (control) to 95% at 10 years with Adjuvant-RT. Secondary outcome measures were biochemical progression-free survival, freedom from non-protocol hormone therapy, safety and patient-reported outcomes. Standard survival analysis methods were used; hazard ratio (HR)<1 favours Adjuvant-RT. RESULTS: Between October 2007 and December 2016, 1396 participants from UK, Denmark, Canada and Ireland were randomised: 699 Salvage-RT, 697 Adjuvant-RT. Allocated groups were balanced with a median age of 65 years. Ninety-three percent (649/697) Adjuvant-RT reported RT within 6 months after randomisation; 39% (270/699) Salvage-RT reported RT during follow-up. Median follow-up was 7.8 years. With 80 distant metastasis events, 10-year FFDM was 93% for Adjuvant-RT and 90% for Salvage-RT: HR=0.68 [95% confidence interval (CI) 0.43-1.07, P=0.095]. Of 109 deaths, 17 were due to prostate cancer. Overall survival was not improved (HR=0.980, 95% CI 0.667-1.440, P=0.917). Adjuvant-RT reported worse urinary and faecal incontinence 1 year after randomisation (P=0.001); faecal incontinence remained significant after 10 years (P=0.017). CONCLUSION: Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy. TRIAL IDENTIFICATION: RADICALS, RADICALS-RT, ISRCTN40814031, NCT00541047.Citation
Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Annals of oncology : official journal of the European Society for Medical Oncology. 2024 Jul;35(7):656-66. PubMed PMID: 38583574. Epub 2024/04/08. eng.Journal
Annals of OncologyDOI
10.1016/j.annonc.2024.03.010PubMed ID
38583574Additional Links
https://dx.doi.org/10.1016/j.annonc.2024.03.010Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2024.03.010
Scopus Count
Collections
Related articles
- Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
- Authors: Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, Cross W, Logue J, Parulekar W, Payne H, Persad R, Pickering H, Saad F, Anderson J, Bahl A, Bottomley D, Brasso K, Chahal R, Cooke PW, Eddy B, Gibbs S, Goh C, Gujral S, Heath C, Henderson A, Jaganathan R, Jakobsen H, James ND, Kanaga Sundaram S, Lees K, Lester J, Lindberg H, Money-Kyrle J, Morris S, O'Sullivan J, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, Røder MA, Sayers I, Simms M, Wilson J, Zarkar A, Parmar MKB, Sydes MR
- Issue date: 2020 Oct 31
- Radical prostatectomy versus deferred treatment for localised prostate cancer.
- Authors: Vernooij RW, Lancee M, Cleves A, Dahm P, Bangma CH, Aben KK
- Issue date: 2020 Jun 4
- Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
- Authors: Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH
- Issue date: 2024 Dec 1
- Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
- Authors: Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE
- Issue date: 2021 Dec
- Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer.
- Authors: Flores JM, Vertosick EA, Salter CA, Liso N, Teloken P, Berookhim B, Jenkins L, Carlsson S, Laudone V, Eastham J, Vickers AJ, Mulhall JP
- Issue date: 2025 Jan